Atara Biotherapeutics (ATRA) Net Income (2013 - 2026)

Atara Biotherapeutics (ATRA) has reported Net Income for 14 consecutive years, with -$4.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Net Income fell 302.51% year-over-year to -$4.8 million; the trailing twelve-month figure through Jun 2026 stood at -$23.5 million (down 505.69% YoY), and the FY2025 full-year result was $25.9 million, up 130.29% from the prior year.
• Net Income fell to -$4.8 million in Q2 2026 per ATRA's latest filing, from -$4.1 million in the prior quarter.
• Across five years, Net Income topped out at $38.0 million in Q1 2025 and bottomed at -$88.1 million in Q1 2022.
• Historically, Net Income has averaged -$31.8 million across 5 years, with a median of -$20.5 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Net Income plunged 485.08% in 2023, then surged 219.71% in 2025.
• Over 5 years, Net Income stood at -$74.7 million in 2022, then gained by 18.72% to -$60.7 million in 2023, then surged by 79.09% to -$12.7 million in 2024, then grew by 19.42% to -$10.2 million in 2025, then surged by 52.74% to -$4.8 million in 2026.
• According to Business Quant data, Net Income over the past three periods registered -$4.8 million, -$4.1 million, and -$10.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.